Log inSign up
BridgeBio Pharma
1,002 posts
BridgeBio Pharma profile banner
@BridgeBioPharma

BridgeBio Pharma

@BridgeBioPharma
We move at the speed of patient need. We exist to bring meaningful medicines to people living with genetic conditions. $BBIO
Palo Alto, California
bridgebio.com
Joined January 2021
165
Following
2,074
Followers
RepliesRepliesRepostsRepostsMediaMedia

Log in or sign up for X

See what’s happening and join the conversation

Continue with phone
or
Log in with username or email
Terms·Privacy·Cookies·Accessibility·Ads Info·© 2026 X Corp.
  • @BridgeBioPharma
    BridgeBio Pharma
    @BridgeBioPharma
    1h
    $BBIO management will join fireside chats at 4 healthcare investor conferences this Sept: @WellsFargo Healthcare Conf – Boston, 9/9, @Official_Cantor Global Healthcare Conf – NYC, 9/10, @MorganStanley Healthcare Conf – NYC, 9/1, & Bernstein Healthcare Leaders – NYC, 9/23. Learn
  • @BridgeBioPharma
    BridgeBio Pharma
    @BridgeBioPharma
    Aug 30
    New analyses in ATTR-CM were presented at @ESCcardio #ESC2026, including serial cardiac MRI data through Month 42 and open-label extension data through Month 54. Read the full release: bit.ly/46sS41O
  • @BridgeBioPharma
    BridgeBio Pharma
    @BridgeBioPharma
    Aug 28
    Thank you, Ashley, for sharing your story with us. Your voice offers insight and hope to others living with #EPP and reminds us why these conversations matter. Listen on the #OnRarePodcast: bit.ly/4yWorTK
  • @BridgeBioPharma
    BridgeBio Pharma
    @BridgeBioPharma
    Aug 27
    No clinic. No cost. Our mobile #genetictesting van is bringing answers directly to families across the West Coast – and once we find a person with ADH1, we can test the whole family. Follow the tour. #ADH1
    00:00
  • @BridgeBioPharma
    BridgeBio Pharma
    @BridgeBioPharma
    Aug 26
    First participant dosed in ASCEND-ATTR, a Phase 3b/4 study evaluating the long-term effects of acoramidis on cardiac structure, function & amyloid burden in ATTR-CM. This builds on our CMR substudy findings from ATTRibute-CM, which we will share updated data for at @escardio